HUMA · Company research
Humacyte, Inc. Common Stock (HUMA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note | Humacyte, Inc. (HUMA) stock declined 6.5% to $0.40 per share, underperforming broader market gains. The biomedical company has lost 26.74% over the past month. While earnings are expected to improve with EPS up 35.71% year-over-year and revenue projected to rise 14.67%, full-year estimates show concerning trends with earnings down 53.85% and revenue growth of 98.48%. The stock currently holds a Zacks Rank of #3 (Hold). | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bearish | -1 | 1 |
| Humacyte, Inc. (HUMA) Stock Price, News, Quote & History - Yahoo! Finance Canada | Humacyte, Inc. (HUMA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| 49 hospitals ordered a bioengineered blood vessel. Several surgeons submitted patient case studies for presentations. - Stock Titan | 49 hospitals ordered a bioengineered blood vessel. Several surgeons submitted patient case studies for presentations. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know | Humacyte, Inc. (HUMA) declined 7.88% to close at $0.36, significantly underperforming the broader market. The stock has lost 30.55% over the past month, lagging the Medical sector's gains. Analysts expect the company to report a loss of $0.09 per share in the upcoming earnings release, though this represents a 35.71% year-over-year improvement. The company holds a Zacks Rank of #3 (Hold), with the Medical - Biomedical and Genetics industry ranked in the bottom 35% of all industries. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bearish | -1 | 1 |
| Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance | Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| A trial compares two blood-vessel options for women on dialysis. Interim results will be presented Oct. 22. - Stock Titan | A trial compares two blood-vessel options for women on dialysis. Interim results will be presented Oct. 22. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| $HUMA stock is down 11% today. Here's what we see in our data. - Quiver Quantitative | $HUMA stock is down 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 9, 2026 | neutral | 0 | 0.6 |
| Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts - Yahoo Finance | Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade | Humacyte, Inc. (HUMA) closed at $0.48, down 4.26% on a day when major market indices gained. The stock has declined 17.34% over the past month, underperforming the Medical sector. The company is expected to report an EPS of -$0.09 and revenue of $0.86 million in its upcoming earnings release. Humacyte currently holds a Zacks Rank of #4 (Sell), and its industry ranks in the bottom 28% of all industries. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bearish | -1 | 1 |
| Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance | Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note | Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note | Humacyte, Inc. (HUMA) stock declined 2.86% to $0.50, underperforming broader market gains. The stock has lost 13.23% over the past month. While the company expects EPS to improve 35.71% next quarter with revenue up 14.67%, full-year projections show earnings declining 53.85% despite revenue doubling. The stock holds a Zacks Rank #4 (Sell) rating, and its industry ranks in the bottom 27% of all sectors. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -1 | 1 |
| Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance | Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Yahoo Finance | View source ↗ | Yahoo Finance | Oct 1, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance | Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 18, 2026 | neutral | 0 | 0.6 |
| $HUMA stock is down 8% today. Here's what we see in our data. - Quiver Quantitative | $HUMA stock is down 8% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 31, 2026 | neutral | 0 | 0.6 |
| Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq - Stock Titan | Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo | Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results Moomoo | View source ↗ | Moomoo | Aug 20, 2026 | neutral | 0 | 0.6 |
| Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance | Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance | Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds Yahoo Finance | View source ↗ | Yahoo Finance | Aug 13, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance | Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Jul 21, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance | Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
| Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data - Yahoo Finance | Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data Yahoo Finance | View source ↗ | Yahoo Finance | Jun 27, 2026 | neutral | 0 | 0.6 |
| Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance | Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Apr 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.